Mayne Pharma Group Limited (ASX:MYX) presented its Annual General Meeting business update on 20 November 2026, disclosing full-year FY26 revenue of $383.7 million, a gross margin of 64.7%, and underlying EBITDA of $34.2 million, alongside details of a Cosette transaction and the launch of its DistributeRx business.

Key Points

  • FY26 revenue was $383.7 million, down 6% from FY25, with gross margin rising to 64.7% from 60.6% in FY25
  • Underlying EBITDA of $34.2 million, down 27% from $47.0 million in FY25
  • Cash and marketable securities stood at $80.0 million at 30 June 2026, down from $100.4 million in FY25
  • The company received $14.4 million from Cosette in full satisfaction of FY25 court-ordered legal costs and interest
  • DistributeRx launched in March 2026, with a new automated facility planned to deliver a seven-fold increase in capacity over two phases

FY26 Financial Results

Mayne Pharma reported FY26 revenue of $383.7 million, down 6% from FY25, with a gross margin of 64.7%, up 4.1 percentage points from 60.6% in FY25. Total direct segment contribution was $107.1 million, down 2% from $109.7 million in FY25. Adjusted operating cashflow from continuing operations, excluding a class action settlement and tax refund in FY25 and scheme transaction and litigation costs in FY26, was $34.5 million, down 24% from $45.4 million in FY25. Underlying EBITDA, a non-IFRS measure excluding earn-out reassessments, restructuring charges, class action settlement costs, derivative fair value adjustments and litigation expense, was $34.2 million, down 27% from $47.0 million in FY25.

Branded Portfolio and DistributeRx Launch

According to the filing, branded product sales represented 83% of Mayne Pharma's net sales in FY26, compared with 79% in FY25 and 68% in FY24, with the gross margin rising from 56% in FY24 to 61% in FY25 and 65% in FY26. The company launched DistributeRx in March 2026, described in the filing as a healthcare solutions business that partners with manufacturers to streamline the prescription distribution process and expand patient access to medications. The filing stated DistributeRx significantly exceeded expectations in FY26, with a new automated facility expected to deliver a seven-fold increase in capacity over two phases. The company also disclosed a realignment of its Women's Health sales force, including refreshed sales and marketing materials and dedicated menopause and contraception field representation.

Cosette Transaction and Legal Matters

The filing disclosed that the Cosette transaction process and subsequent legal matters placed considerable demands on management focus and organisational bandwidth during FY26, including general disruption to the Mayne Pharma business. Mayne Pharma received $14.4 million from Cosette in full satisfaction of FY25 court-ordered legal costs and interest. The Court of Appeal upheld a ruling of October 2025, as referenced in a company disclosure dated 14 October 2026. The filing noted that Mayne Pharma's damages claim against Cosette continues. The AGM presentation also referenced a Scheme Implementation Deed attached to a company disclosure dated 17 November 2026.